Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5946372 | Atherosclerosis | 2013 | 6 Pages |
Abstract
ABT-335 therapy reduced fasting and postprandial triglycerides in patients with metabolic syndrome. Autologous HDL may be dysfunctional in these patients as co-incubation with HDL failed to reduce oxidative susceptibility of LDL. During ABT-335 therapy, LDL was less susceptible to Cu++-mediated oxidative modification, in spite of the lack of changes in LDLc levels.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ngoc-Anh Le, Monica Farkas-Epperson, Mary Ellen Sweeney, Peter W.F. Wilson, W. Virgil Brown,